Once-weekly (70 mg/m2) versus twice weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

被引：0
|
作者：
Moreau, Philippe
Stewart, A. Keith
Dimopoulos, Meletios A.
Siegel, David Samuel DiCapua
Facon, Thierry
Berenson, James R.
Raje, Noopur S.
Berdeja, Jesus G.
Orlowski, Robert Z.
Yang, Hui
Ma, Haijun
Karina Klippel, Zandra
Zahlten-Kumeli, Anita
Mezzi, Khalid
Iskander, Karim
Mateos, Maria-Victoria
机构：
[1] Univ Hosp Nantes, Nantes, France
[2] Mayo Clin, Scottsdale, AZ USA
[3] Univ Athens, Athens, Greece
[4] Hackensack Univ Med Ctr, Hackensack, NJ USA
[5] Reg Univ Hosp Lille, Lille, France
[6] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[7] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Univ Salamanca Hosp, IBSAL, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19505
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [32] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR
    Takezako, Naoki
    Shibayama, Hirohiko
    Handa, Hiroshi
    Hagiwara, Shotaro
    Ozaki, Shuji
    Suzuki, Kenshi
    Kosugi, Hiroshi
    Ri, Masaki
    Sugiura, Isamu
    Choi, Ilseung
    Miyamoto, Toshihiro
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (02) : 219 - 230
  • [33] CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael
    Tzachanis, Dimitrios
    Agajanian, Richy
    Boccia, Ralph
    Coleman, Morton
    Moss, Robert A.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Anderl, Janet
    Aggarwal, Sanjay
    Berdeja, Jesus G.
    BLOOD, 2016, 127 (26) : 3360 - 3368
  • [34] Once-Weekly 1.6mg/m2 Bortezomib BCD Regimen in Newly Diagnosed Multiple Myeloma: Better Response and Lower Incidence of Peripheral Neuropathy
    Li, Fangfang
    Li, Hao
    Li, Yubin
    Zhan, Zhumei
    Song, Wangshan
    Li, Fanglin
    Li, Xiangxin
    Wang, Lingling
    Wang, Yan
    Wang, Luqun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E211 - E211
  • [35] Evaluation of different intermediate melphalan doses (80 mg/m2 vs 100 mg/m2 vs 120 mg/m2) in multiple myeloma patients.
    Palumbo, A
    Triolo, S
    Argentino, C
    Bringhen, S
    Dominietto, A
    Giaccone, L
    Rus, C
    Omedè, P
    Pileri, A
    Boccadoro, M
    BLOOD, 1999, 94 (10) : 578A - 578A
  • [36] A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Lendvai, Nikoletta
    Hilden, Patrick
    Devlin, Sean
    Landau, Heather
    Hassoun, Hani
    Lesokhin, Alexander M.
    Tsakos, Ioanna
    Redling, Kaitlyn
    Koehne, Guenther
    Chung, David J.
    Schaffer, Wendy L.
    Giralt, Sergio A.
    BLOOD, 2014, 124 (06) : 899 - 906
  • [37] Carfilzomib 20/45 or 20/56 mg/m2 infused over 30 min in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Badros, Ashraf
    Papadopoulos, Kyriakos P.
    Zojwalla, Naseem
    Ruey, Ju
    Lee, Jiuan
    Siegel, David S.
    LEUKEMIA & LYMPHOMA, 2013, 54 : 17 - 18
  • [38] ARROW2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Dimopoulos, Meletios A.
    Coriu, Daniel
    Delimpasi, Sosana
    Spicka, Ivan
    Upchurch, Terry
    Fang, Belle
    Talpur, Rakhshandra
    Faber, Edward
    Beksac, Meral
    Leleu, Xavier
    BLOOD ADVANCES, 2024, 8 (19) : 5012 - 5021
  • [39] Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM)
    White, Darrell
    Schiller, Gary J.
    Madan, Sumit
    Lentzsch, Suzanne
    Chubar, Evgeni
    Lavi, Noa
    Van Domelen, Dane R.
    Bentur, Ohad S.
    Baljevic, Muhamed
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
    Leleu, Xavier
    Beksac, Meral
    Chou, Takaaki
    Dimopoulos, Meletios
    Yoon, Sung-Soo
    Prince, H. Miles
    Pour, Ludek
    Shelekhova, Tatiana
    Chari, Ajai
    Khurana, Monica
    Zhang, Jianqi
    Obreja, Mihaela
    Qi, Ming
    Oriol, Albert
    Siegel, David
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 358 - 367
12345